drugset / Trial / NCT03414918

Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)

NCT03414918

NaSingle-groupOpen-labelDiagnostic

Summary

This study evaluates if : 1 ) the plasma aldosterone concentration and blood pressure change in response to roxithromycin could be useful for the screening of PA patients carrying a KCNJ5-mutated APA; 2) the change of PAC in response to mutated KCNJ5 channel is truly occurring in KCNJ5-mutated APA.

Timeline

Start
2018-03
Primary completion
2019-01
Completion
2020-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 250 mg Intravenous
Subject roxithromycin Small molecule 150 mg Oral

Indications